+1803294983432
customer.service@microbix.com
Childhood Disease Antigen Products
Microbix is at the leading edge of manufacturing native antigens for IVD industry leaders specializing in childhood disease immunological test development.
Setting the Gold Standard for Infectious Disease Diagnostic Standards
Decades of Diagnostics Excellence
For almost three decades, our antigens have been of the highest reliability and quality for diagnostic companies worldwide.
Superior Quality Controls
Our antigen products are excellent positive quality controls for diagnostics assays.
Precise Antigen Solutions
Our extensive antigen panels are fit for any level of immunoassay you require.
Download Our Full Product Catalogue
Products
| Product Name | Catalogue Number | Description |
| Rubella BR2S | EL-05-15 | Description: The predominant form of the native antigen is whole virions suspended in NTE with sucrose. The preparation is free of detergent. Residual non-viral protein may come from host tissue and culture medium. Strain: HPV-77 Buffer: NTE buffer (Sodium chloride, TRIS and EDTA)
|
| Varicella-Zoster, Grade 2 | EL-03-02 | Description: The resulting native antigen preparation contains a high concentration of virus and viral components as well as some cellular material suspended in EMEM with some serum proteins. Strain: VZ-10 Buffer: EMEM
|
| P3H3 Cell Extract | EL-16-03 | Description: P3H3 Cell Extract contains a high concentration of native Epstein-Barr Virus antigens, including VCA, EBNA, EA-D, and EA-R. Strain: P3H3 Human Burkitt’s Lymphoma cells Buffer: Tris with NP40, sodium deoxycholate and PMSF
|
| EBV Viral Capsid Ag, Purified | EL-16-06 | Description: This preparation contains more than 90% virus specific protein. The predominant form of the native antigen is purified protein suspended in 20mM Tris-HCl with 3M MgCl,; pH 7.4. The preparation is free of detergent. Any residual non-viral protein comes from host tissue and culture medium. Strain: P3H3 cells infected with EBV Buffer: 20mM Tris-HCl with 3M MgCl2; pH 7.4
|
| EBV Viral Capsid Concentrate | EL-16-07 | Description: This preparation contains more than 90% virus specific protein. The predominant form of the antigen is purified protein suspended in 20mM Tris-HCl with 3M MgCl2; pH 7.4. The preparation is free of detergent. Residual non-viral protein comes from host tissue and culture medium. Strain: P3H3 cells infected with EBV Buffer: 20mM Tris-HCl with 3M MgCl2; pH 7.4
|
| Measles, Grade 2 | EL-04-02 | Description: The resulting native antigen preparation contains a high concentration of virus and viral components as well as some cellular material suspended in MEM. Strain: Edmonston Buffer: MEM
|
| Mumps, Grade 2 | EL-06-02 | Description: The resulting native antigen preparation contains a high concentration of virus and viral components as well as some cellular material suspended in 1969B. Strain: Enders Buffer: 1969B
|
Frequently Asked Questions
What specific antigens or pathogens are covered by your childhood disease antigen products?
Infectious diseases covered by our childhood disease antigen products include rubella, varicella zoster, P3H3 cell extract, Epstein Barr viral capsid Ag, measles, and mumps.
What is the source and purity of the childhood disease antigens you supply?
Our childhood disease antigens are derived from natural sources.
Are the antigens provided in a ready-to-use form or as raw materials for further processing?
This product is a ‘raw material’ for use by diagnostic manufacturers and other customer groups.
What is the shelf life of your childhood disease antigen products?
The shelf life of our childhood antigens is two years from the shipping date.
Are these antigens suitable for diagnostic tests, vaccine development, or research purposes?
These viral, bacterial, and parasitic antigen products are used in immunodiagnostic assays including ELISA, chemiluminescent automated immunoassays, immunohistochemistry, immunofluorescence, latex agglutination, rapid tests, and flow cytometry. Our childhood disease antigens are also used as external quality controls for diagnostic assays, basic and applied research in virology, microbiology, cell biology, immunology, and pathology, and for vaccine and antiviral research and development.
Testimonials
Proudly Supporting Over 100+ Customers with Leading Diagnostic Solutions
Learn more about how our clients worldwide use Microbix’s product lines to enhance the way they do business.
We considered other external quality controls but selected Microbix QAPs as the best solution to support assay optimization and to significantly simplify QC procedures with minimal to no pipetting steps. Microbix’s technical expertise, product design, performance, and superior customer service are impressive. We look forward to continuing our collaboration.
Robert Martinez, VP of Business Development & Scientific Affairs
We were looking for a set of controls that fully covered the range of high-risk HPV types and Microbix is the only company to have such a portfolio. After an extensive evaluation process, we concluded the performance of Microbix QAPs are exactly what Ulisse needs and the interactions with their team are delightful.
Bruna Marini, COO
MDx testing for HPV improves cervical cancer screening by identifying those at-risk efficiently. Close monitoring of the entire HPV testing workflow is critical to realizing this healthcare goal and Microbix’s HPV QAPs have been selected to support the quality assessment monitoring of the molecular testing process, a vital part of BVO’s quality management system
Dr. Rob Schuurman, National Reference Officer for the Dutch Cervical Cancer Screening Program (BVO)
r-Biopharm is pleased that the program will be delivering world-class diagnostic testing to some of the most remote populations in Australia. It has been a privilege to work with the program’s operational team and Microbix to integrate the use of the best possible test and test-workflow controls into the program
Andreas Simons, Director, Project Management Clinical Diagnostics
We’re pleased to be employing Microbix’s innovative QAPs for this new and important EQA program. Genital ulcers are the cause of a considerable and growing burden of disease that can only be alleviated by way of accurate diagnosis and treatment
Juha Wahlstedt, Sales Director at Labquality
Microbix approached us before the pandemic started, and the relationship developed so easily and quickly that we formalized our collaboration in 2020. Along with their excellent technical capabilities, they have successfully developed relationships with many diagnostics manufacturers around the world. We are pleased that our FLOQSwabs® are their exclusive choice for their growing line of swab formatted QAPs™.
Gaetano Natale, Chief Commercial Officer.
We’ve been using Microbix’s External Quality controls for 3 years specifically from their Respiratory and Sexually Transmitted Infections panels on our instruments. It has helped us ensure accurate and reliable patient results and we’ve been delighted with their performance.
Alfie Zhen Fang, Buyer, Procurement
Your Trusted Childhood Disease Antigen Supplier
Microbix has constantly improved how we culture, isolate, and purify the viruses, with the result that many of the world’s largest diagnostic manufacturers have made our childhood disease antigens their #1 choice.
The childhood disease native antigens product panel includes rubella, varicella zoster, P3H3 cell extract, Epstein Barr viral capsid Ag (purified and concentrated), measles, and mumps.
Speak to a Childhood Disease Antigen Customer Service Representative
Let our knowledgeable experts help you secure your childhood disease antigen products today.
News & Insights from Our Diagnostics Experts
Microbix Presenting at Investor Conference in B.C.
announces that it will be presenting to equity investors at the Whistler Capital Event conference, organized by Capital Event Management Ltd. and being hosted at the Fairmont Chateau Whistler, in Whistler, Brit...
Microbix Reports Strong Revenues & Earnings for Q1 Fiscal 2025
reports results for its first quarter of fiscal 2025 ended December 31, 2024 (“Q1”)....
Microbix Schedules Release of Results for Q1 Fiscal 2025
announces that it expects to file the financial statements and management disclosure and analysis for its first quarter of fiscal 2025 ended December 31, 2024 (“Q1 2025”) prior to the start of trading on Fe...